0
™
Corporate Presentation
GIAPREZA™ (angiotensin II) Update
NASDAQ: LJPC
December 2017
1
Forward Looking Statement
These slides contain forward-looking statements as that term is defined in the Private Securities Litigation
Reform Act of 1995. These statements relate to expectations regarding future events or La Jolla’s future
results of operations. These statements are only predictions or statements of current expectations and
involve known and unknown risks, uncertainties and other factors that may cause actual results to be
materially different from those anticipated by the forward-looking statements. La Jolla cautions readers not to
place undue reliance on any such forward-looking statements, which speak only as of the date they were
made. Certain of these risks, uncertainties and other factors are described in greater detail in La Jolla’s
filings with the U.S. Securities and Exchange Commission (SEC), all of which are available free of charge on
the SEC’s website www.sec.gov. These risks include, but are not limited to, risks relating to: the timing for
commercial launch of GIAPREZA (angiotensin II); the degree of physician or pharmacy and therapeutics
committee adoption of GIAPREZA and La Jolla’s success in commercializing GIAPREZA; the timing and
availability of GIAPREZA in the market; the anticipated treatment of future clinical data by the FDA, the EMA
or other regulatory authorities, including whether such data will be sufficient for approval of GIAPREZA in the
EMA and for approval of other product candidates by either the FDA or EMA; risks relating to the scope of
the GIAPREZA product label; potential market sizes, including for septic or other distributive shock; potential
indications for which La Jolla’s products and product candidates may be developed; the anticipated timing for
regulatory actions; the timing, costs, conduct and outcome of clinical studies; the impact of pharmaceutical
industry regulation and healthcare legislation in the United States; and the success of future development
activities. La Jolla expressly disclaims any intent to update any forward-looking statements to reflect the
outcome of subsequent events.
2
GIAPREZA™ Now Approved
GIAPREZA (angiotensin II) Injection for Intravenous Infusion is indicated
to increase blood pressure in adults with septic or other distributive shock
"We appreciate FDA's rapid review and
approval of GIAPREZA and are
especially grateful to the patients,
families and dedicated critical care
teams who made the development of
GIAPREZA possible," said George F.
Tidmarsh, M.D., Ph.D., President and
Chief Executive Officer of La Jolla. "We
look forward to bringing this new
treatment option to the many critically ill
patients suffering from septic or other
distributive shock."
"Shock, the inability to maintain blood flow to vital
tissues, can result in organ failure and death," said
Norman Stockbridge, M.D., Ph.D., director of the
Division of Cardiovascular and Renal Products in
the FDA’s Center for Drug Evaluation and Research.
"There is a need for treatment options for critically ill
hypotensive patients who do not adequately
respond to available therapies."
GIAPREZA is classified as a new chemical entity exclusivity
(NCE) with 5 years of market exclusivity
3
Mission Statement
La Jolla is dedicated to improving the lives of
patients suffering from life-threatening diseases
by discovering and developing innovative
therapies
3
4
Shock
MORTALITY RATES COMPARED
Shock: Deadly, Costly and Prevalent
1. Vincent JL, De Backer D. N Engl J Med. 2013;369(18):1726-1734. 2. Sviri S, Hashoul J, Stav I, van Heerden PV. J Crit Care. 2014;29(1):157-160. 3. Readmissions
and deaths-national. Data.Medicare.gov website. https://data.medicare.gov/Hospital-Compare/Readmissions-and-Deaths-National/qqw3-t4ie/data. Accessed January 10,
2017
Abbreviations: AMI=acute myocardial infarction; CHF=congestive heart failure.
4
• A well-characterized syndrome1
Occurs when the organs and tissue of the body
do not receive an adequate flow of blood
(oxygen) due to a lack of blood pressure
(hypotension)
• Deadly
Mortality rate exceeds that of most acute
conditions requiring hospitalization2
Can kill old and young alike within hours2
• Costly
Estimated costs are 2-3 times greater
compared to other conditions
• Prevalent
Affects one-third of patients in the intensive
care unit1
30-day mortality rate3
14% 12%
16%
AMI CHF Pneumonia
≥50% mortality
in patients with
shock in the
ICU2
5
Prevalence Types of Shock
Distributive Shock is the Most Common
Type of Shock in the Inpatient Setting1
1. Vincent JL, De backer D. Circulatory shock. N Engl J Med. 2013;369(18):1726-34.
Distributive
(94% is Septic Shock)
Obstructive
66%
16%
16%
Cardiogenic
Hypovolemic
Distributive Shock Hypovolemic Shock
Obstructive ShockCardiogenic Shock
2%
Hypotension, or Abnormally Low Blood Pressure, is an Important Hemodynamic Marker for a Vasodilatory or Distributive Shock
6
Distributive Shock is Costly
Source: CMS FY14 Inpatient Public Use File (IPUF)
$87,282
$42,243
$31,453 $30,702
Severe Distributive
Shock
AMI CHF Pneumonia
Weighted Average CMS Covered Charges
Abbreviations: AMI=acute myocardial infarction; CHF=congestive heart failure.
An average day in the
ICU costs between
$4,500 to $6,000
Mechanical ventilation
adds ~$1,500
Hospitals are implementing multiple
quality initiatives to improve patient
care and maximize CMS
reimbursements
7
GIAPREZA Provides a New Approach For
Increasing Blood Pressure In Distributive Shock
THERAPIES AND MECHANISMS
SYMPATHETIC
NERVOUS
ARGININE-
VASOPRESSIN
RENIN
ANGIOTENSIN-
ALDOSTERONE
7
CATECHOLAMINES1: SYMPATHETIC NERVOUS
VASOPRESSIN: ARGININE-VASOPRESSIN
GIAPREZA™
(angiotensin II)
Injection for Intravenous Infusion
RENIN ANGIOTENSIN-ALDOSTERONE
1. Catecholamines include: norepinephrine, epinephrine, dopamine, phenylephrine, ephedrine
8
GIAPREZA: A Novel Vasopressor For
Patients with Distributive Shock
A Unique Mechanism of Action - First and only synthetic human
angiotensin II
Robust Response - 70% Patients achieved and maintained target MAP
primary endpoint at hour 3
Rapid Response - Median response time to reach target MAP was 5
minutes
Mortality trend – Mortality through Day 28 was 46% on GIAPREZA and
54% on placebo (hazard ratio 0.78; 95% confidence interval 0.57 – 1.07)
Sustained Response – Maintained throughout the treatment period
Safety – Percent of patients with AEs were similar between the two
treatment arms
• There is a potential for venous and arterial thromboembolic events
(AEs 12.9% v 5.1%, DVT SAEs 1.8% v 0%)
• May be prevented by use of concurrent venous thromboembolism
prophylaxis
Abbreviations: MAP=Mean Arterial Pressure; AEs=Adverse Events; SAEs=Serious Adverse Events; DVT=Deep Vein Thrombosis
9
Distributive Shock is Prevalent
9
1. Standard of Care percentages estimated lines of therapy calculations based on Second Line estimate. Percentages based on Vincent JL, De backer D. Circulatory shock. N Engl J
Med. 2013;369(18):1726-34 and Decision Resources Group market research.
2. SHA Integrated Pack Units from Aug 2017 – Jul 2017 3.01M, Filtered for hospitals, applying an estimated 10% stocking adjustment, inpatient percentage and average vials/patient
based on Premier data inpatient Vasostrict patients projected to national numbers
Distributive
Shock Patients
First Line
Standard of Care
Second-Line
Standard-of-Care
555,479
361,684
332,189
313,000 Patients2
per Year
745,000 Patients per Year1
808,000 Patients per Year1
10
Preparing For Commercialization in 2018
Commercial
• Market Research
• Healthcare Professional Marketing
• Multi-Channel Marketing
• Professional Education
• Commercial Insights & Operations
• Market Access
Field Sales
• National and Regional Sales Leadership*
• Critical Care Nurse Educators*
• Hospital Critical Care Field Representative*
• Market Access Team*
• Sales Training
• Field Trade
*136 Customer Facing FTEs
Medical Affairs
• Medical Science Liaisons*
• Medical Communications
• HEOR Team
• Medical Education
11
Financial Position
Condensed Balance Sheet Data As of September 30, 2017
(in millions)
Cash $120.8
Total liabilities $10.3
Total shareholders’ equity1 $119.8
Fully Diluted, As-Converted
Shares Outstanding1
34,017,102
1 Includes common stock, preferred stock (as-converted), and outstanding equity awards as of September 30, 2017
Cash resources expected to fund Company into second half of 2018
12
Thank You
™